Compare OTLY & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OTLY | FBRX |
|---|---|---|
| Founded | 1994 | N/A |
| Country | Sweden | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 320.7M | 487.2M |
| IPO Year | 2021 | 2017 |
| Metric | OTLY | FBRX |
|---|---|---|
| Price | $13.02 | $31.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $14.50 | ★ $67.00 |
| AVG Volume (30 Days) | 63.7K | ★ 382.1K |
| Earning Date | 04-29-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | $7.91 | N/A |
| Revenue Next Year | $5.50 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.42 | $4.91 |
| 52 Week High | $18.84 | $35.80 |
| Indicator | OTLY | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 72.39 | 57.72 |
| Support Level | $11.50 | $26.67 |
| Resistance Level | $18.41 | $31.71 |
| Average True Range (ATR) | 0.61 | 3.49 |
| MACD | 0.37 | 0.81 |
| Stochastic Oscillator | 96.44 | 64.25 |
Oatly Group AB produces and distributes oat-based food and beverage products. Its offerings include milk, cooking creams, spreads, and yogurts. The company's products are sold through retail stores, coffee shops, and restaurants across multiple countries. It generates revenue from sales of oatmilk and other oat-based products. The company's geographical segments include Europe & International, North America and Greater China. The Europe & International segment is its maximum revenue-producing segment, followed by the North America and Greater China segments.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.